NMRA Neumora Therapeutics Forecast, Technical & Fundamental Analysis
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed... Show more
NMRA is expected to report earnings to rise 17.39% to -27 cents per share on November 04
Q3'26
Est.
$-0.27
Q2'26
Beat
by $0.04
Q1'26
Est.
$-0.30
Q4'25
Beat
by $0.12
Q3'25
Beat
by $0.10
The last earnings report on August 14 showed earnings per share of -23 cents, beating the estimate of -27 cents. With 337.47K shares outstanding, the current market capitalization sits at 306.27M.
A.I.dvisor indicates that over the last year, NMRA has been loosely correlated with SLBT. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if NMRA jumps, then SLBT could also see price increases.
NMRA saw its Stochastic Oscillator recovers from the overbought zone
The Stochastic Oscillator for NMRA moved out of overbought territory on August 14, 2026. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 33 similar instances where the indicator exited the overbought zone. In of the 33 cases the stock moved lower. This puts the odds of a downward move at .
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for NMRA turned negative on August 17, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 19 similar instances when the indicator turned negative. In of the 19 cases the stock turned lower in the days that followed. This puts the odds of success at .
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on August 21, 2026. You may want to consider a long position or call options on NMRA as a result. In of 45 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
NMRA moved above its 50-day moving average on August 21, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for NMRA crossed bullishly above the 50-day moving average on August 07, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 5 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where NMRA advanced for three days, in of 162 cases, the price rose further within the following month. The odds of a continued upward trend are .
NMRA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.878) is normal, around the industry mean (20.145). P/E Ratio (0.000) is within average values for comparable stocks, (22.992). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.861). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (444.692).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. NMRA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NMRA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.
